UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of: April, 2004
Commission File Number: 000-50393
NEUROCHEM INC.
7220 Frederick-Banting, Suite 100
Saint-Laurent, Quebec
H4S 2A1
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
April 13, 2004
By: /s/David Skinner
---------------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
NEUROCHEM INC.
7220 Frederick-Banting, suite 100
[LOGO (NEUROCHEM)] Saint-Laurent, Quebec H4S 2A1
________________________________________________________________________________
NEUROCHEM INVITED TO PRESENT FINDINGS ON ALZHEIMER DRUG
TO SPRINGFIELD CONFERENCE
SYMPOSIUM HIGHLIGHTS NEUROCHEM'S ALZHEMED(TM) AS ONE OF THE MOST PROMISING
PRODUCT CANDIDATES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
MONTREAL, APRIL 13 , 2004 - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM) announced
today that it has been chosen as one of the five group of researchers and
companies that will be highlighted at the 8th International Montreal/Springfield
Symposium on Advances in Alzheimer Therapy. This prestigious event is expected
to gather more than 600 experts in the etiology and treatment of Alzheimer's
Disease (AD). A press conference to announce the event will be held on April
14th at 12h30 in the Matapedia Room of the Fairmont Queen Elizabeth hotel in
Montreal.
ABOUT NEUROCHEM'S PRESENTATIONS DURING THE SYMPOSIUM
Dr. Francine Gervais, Ph.D., Neurochem's Vice-President, Research and
Development, will present the Company's Glycosaminoglycan (GAG) Mimetic
technology platform and explain how it would prevent the formation of amyloid
fibrils in the brain. She will also describe how in the three-month randomized
Phase II clinical trial, Neurochem's product candidate, Alzhemed(TM), was found
to markedly reduce the concentration of amyloid (B) (A(B)) protein in the
cerebrospinal fluid of treated patients in a dose-dependent fashion. Dr.
Gervais' presentation will be made on Saturday, April 17, 2h10 P.M.
Denis Garceau, Ph.D., Neurochem's Vice-President, Drug Development, Dr. Garceau
will describe the design of the Alzhemed(TM) Phase II clinical trial and then
review the clinical results in Alzheimer patients after both the three-month
randomized trial and up to 16 months of the on-going open-label extension study
(OLES). Dr. Garceau's presentation will be held on Thursday, April 15, 5h30-7h30
P.M.(poster).
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying, oral products addresses critical unmet medical needs.
Fibrillex(TM), designated as an orphan drug and as Fast Track Product candidate,
is in a Phase II/III clinical trial for the treatment of AA amyloidosis.
Alzhemed(TM) and Cerebril(TM) have completed a Phase II clinical trial for the
treatment of Alzheimer's disease and for the prevention of hemorrhagic stroke
caused by cerebral amyloid angiopathy respectively. For additional information
on Neurochem, please visit our website at: (www.neurochem.com).
All of the statements contained in this news release, other than statements of
fact that are independently verifiable at the date hereof, are forward-looking
statements. Such statements, based as they are on the current expectations of
management, inherently involve numerous risks and uncertainties, known and
unknown. Some examples of known risks are: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the
regulatory environment in the jurisdictions in which Neurochem does business,
stock market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation or otherwise. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, Ph.D.
Vice President, Corporate Communications
lhebert@neurochem.com
- ---------------------
Tel: (514) 337-4646
Fax: (514) 684-7972